ArticleBMC veterinary research2026
Nephroprotective effect of spexin in dogs and cats.
Article in BMC veterinary research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundKidney disease is a common and clinically significant problem in dogs and cats, yet the underlying pathophysiological mechanisms remain incompletely understood. A large part of the research concerns the role of newly described peptides/proteins that may potentially be involved in these processes. One of the peptides whose role in renal metabolism has not yet been fully understood is spexin (SPX), which has a wide distribution in the body and is involved in the regulation of many physiological processes. The aim of this study was to evaluate SPX concentration in serum from dogs and cats with chronic kidney disease (CKD) and to investigate the potential role of SPX in kidney cell metabolism using an in vitro model based on MDCK and CRFK cells.
resultsOur findings showed a significant reduction in serum SPX levels in animals with CKD (p < 0.01). We also demonstrated, for the first time, the presence of SPX and its receptors GALR2 and GALR3 at the mRNA level in both cell lines. Moreover, we demonstrated that SPX supplementation increased cell viability in both cell lines (MDCK: p < 0.05; CRFK: p < 0.01), without affecting proliferation. Furthermore, SPX reduced the mRNA expression of key fibrotic markers associated with CKD progression, including α-SMA, TIMP1, Col1a, and fibronectin (p < 0.05). These effects were more pronounced following epithelial-mesenchymal transition (EMT) induction with TGF-β1 (p < 0.01).
conclusionTaken together, the obtained results indicate that SPX could be a regulator of kidney cell function and may be a potential therapeutic target in the treatment of kidney diseases in dogs and cats.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.